Pyrrole derivatives and their methods of use

Details Pyrrole derivatives and their methods of use Pyrrole derivatives and their methods of use

2007-06-27

2010-06-22

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S429000, C548S530000, C548S537000, C548S540000

Reexamination Certificate

active

07741364

ABSTRACT:
The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.

REFERENCES:
patent: 2005/0065178 (2005-03-01), Basha et al.
patent: 2005/0137204 (2005-06-01), Ji et al.
patent: 2005/0245531 (2005-11-01), Ji et al.
patent: 0 799 823 (1997-08-01), None
patent: 11-180871 (1999-06-01), None
patent: 01/47880 (2001-05-01), None
patent: 2004/029053 (2004-08-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
DörwaId, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Adler, L.E., et al., “Schizophrenia, Sensory Gating, and Nicotinic Receptors”,Schizophrenia Bull., 24:189-202 (1998).
Albuquerque, E.X., et al., “Modulation of Nicotinic Receptor Activity in the Central Nervous System: A Novel Approach to the Treatment of Alzheimer Disease”,Alz. Dis. &Assoc. Disord., 15(Suppl. 1):S19-S25 (2001).
Alkondon, M. & Albuquerque, E.X., “The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex”,Prog. In Br. Es., 145:109-120 (2004).
Cordero-Erausquin, M. & Changeux, J-P., “Tonic nicotinic modulation of serotoninergic transmission in the spinal cord”,PNAS, 98(5):2803-2807 (2001).
Couturier, S., et al., “A neuronal Nicotinic Acetylcholine Receptor Subunit (α7) Is Developmentally Regulated and Forms a Homo-Oligomeric Channel Blocked by α-BTX”,Neuron, 5:847-856 (1990).
D'Andrea, M.R. & Nagele, R.G., “Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimer's Disease Pyramidal Neurons”,Curr. Pharm. Des., 12:677-684 (2006).
Dajas-Bailador, F. & Wonnacott, S., “Nicotinic acetylcholine receptors and the regulation of neuronal signaling”,Trends in Pharm. Sci., 26(6):317-324 (2004).
Demirayak, S., et al., “Synthesis and cytotoxic and analgesic activities of some 1, 5-diary1-3-ethoycarbonylpyrrole derivatives”,J. of Enz. lnhib. &Medic. Chem., 21(1):113-118 (2006).
Friedman, J.I., et al., “A Double Blind Placebo Controlled Trial of Donepezil Adjunctive Treatment to Risperidone for the Cognitive Impairment of Schizophreniz”,Biol. Psych., 51:349-357 (2002).
Gotti, C., et al., “Brain Neuronal Nicotinic Receptors as New Targets for Drug Discovery”,Curr. Pharm Des., 12:407-428 (2006).
Hajós, M., et al., “The Selective α7 Nicotinic Acetylcholine Receptor Agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] Enhances GABAergic Synaptic Activity in Brain Slices and Restores Auditory Gating Deficits in Anesthetized Rats”,J. of Pharm. &Exp. Ther., 312(3):1213-1222 (2005).
Heeschen, C., et al., “Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis”,Nature Med., 7(7):833-839 (2001).
Heeschen, C., et al., “A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors”.J. of Clin. Invest, 110(4):527-536 (2002).
Hevers, W. & Lüddens, H., “The Diversity of GABA Receptors”,Molec. Neurobiol, 18:35-86 (1998).
Higuchi, T. & Stella. V., “Pro-drugs as Novel Delivery Systems”, vol. 14 of the A.C.S. Symposium Series, (1975).
Hogg, R.C., et al., “Nicotinic acetylcholine receptors: from structure to brain function”,Rev. Physiol. Biochem. Pharmacol., 147:1-46 (2003).
Hunter. B.E., et al., “A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus”.Neurosci. Ltrs., 168:130-134 (1994).
Hurst, R.S., et al., “A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In Vitro and In Vivo Characterization”,J. of Neurosci., 26(17):4396-4405 (2005).
Jonnala, R.R. & Buccalusco, J.J., “Relationship Between the Increased Cell Surface α7 Nicotinic Receptor Expression and Neuroprotection Induced by Several Nicotinic Receptor Agonists”,J. of Neurosci. Res., 66:565-572 (2001).
Keller, J.J., et al, “Performance of α7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task”,Behav. Br. Res., 162:143-152 (2005).
Kihara, T., et al., “α7 Nicotinic Receptor Transduces Signals to Phosphatidylinositol 3-Kinase to Block A β-Amyloid-induced Neurotoxicity”,J. Of. Biol. Chem., 276(17)1:13541-13546 (2001).
Leonard, S., et al., “Smoking and schizophrenia: abnormal nicotinic receptor expression”,Eur. J. of Pharm.,393:237-242(2000).
Levin, E.D., “Nicotinic Receptor Subtypes and Cognitive Function”,J. Neurobiol., 53:633-640 (2002).
Liu. Q-s., et al., “β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons”,PNAS, 98(8):4734-4739 (2001).
Martin, L.F., et al., “Alpha-7 nicotinic receptor agaonists: potential new candidates for the treatment of schizophrenia”.Psychopharm., 174:54-64 (2004).
Paterson, D. & Nordberg, A., “Neuronal nicotinic receptors in the human brain”,Prog. In Neurobiol., 61:75-111 (2000).
Pichat, P., et al., “SSR180711, a novel selective alpha7 nicotinic receptor partial agaonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia”,Soc. For Neurosci., Abstr. #583.3 (2004).
Prescott, D.M., “Methods in Cell Biology”,Academic Press, vol. XIV:Table of Contents (1976).
Roche, ed., E.B., “Bioreversible Carriers in Drug Design”,Amer. Pharm. Assoc. &Perg Press, Tble of Cont.,(1987).
Rowley, M., et al., “Current and Novel Approaches to the Drug Treatment of Schizophrenia”,J. of Medic. Chem., 44(4):477-501 (2001).
Shimohama, S., et al., “Nicotinic α7 receptors protect against glutamate neurotixicity and neuronal ischemic damage”,Brain Res., 779:359-363 (1998).
Son, J.-H., & Meizel, S., “Evidence Suggesting That the Mouse Sperm Acrosome Reaction Initiated by the Zona Pellucida Involves an α7 Nicotinic Acetylcholine Receptor”,Biol of Reprod., 68:1348-1353 (2003).
Stevens, K.E., e al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice”,Psychopharm., 136:320-327 (1998).
Ulloa, L., “The Vagus Nerve and the Nicotinic Anti-Inflammatory Pathway”,Nature Rev., 4(8):673-684 (2005).
Van Kampen, M., et al., “AR-17779 improves social recognition in rats by activation of nicotinic α7receptors”,Psychopharm., 172:375-383 (2004).
Wang, H., et al. “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation”,Nature, 421:384-388 (2003).

Affiliated with

Also associated with

Rating

Pyrrole derivatives and their methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrole derivatives and their methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole derivatives and their methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4160947